CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.049
EU - Europa 930
AS - Asia 747
SA - Sud America 90
OC - Oceania 17
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 3
Totale 2.849
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.039
CN - Cina 414
GB - Regno Unito 248
SG - Singapore 195
RU - Federazione Russa 125
IT - Italia 105
SE - Svezia 104
FR - Francia 97
IE - Irlanda 89
DE - Germania 86
BR - Brasile 84
HK - Hong Kong 36
FI - Finlandia 28
KR - Corea 28
AU - Australia 17
VN - Vietnam 17
IN - India 15
ID - Indonesia 8
TR - Turchia 8
UA - Ucraina 7
AT - Austria 6
BE - Belgio 6
JP - Giappone 6
CA - Canada 5
NL - Olanda 5
PL - Polonia 5
TG - Togo 5
DZ - Algeria 4
EU - Europa 3
IQ - Iraq 3
MX - Messico 3
AR - Argentina 2
AZ - Azerbaigian 2
CH - Svizzera 2
CL - Cile 2
CZ - Repubblica Ceca 2
MA - Marocco 2
NO - Norvegia 2
RO - Romania 2
TW - Taiwan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EC - Ecuador 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NG - Nigeria 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SM - San Marino 1
Totale 2.849
Salva come PNG Salva come JPEG
Città #
Chandler 293
Southend 229
Singapore 137
Beijing 116
Dublin 89
Woodbridge 83
Ann Arbor 48
Ashburn 47
Wilmington 41
Lawrence 40
Princeton 40
Hong Kong 36
Jinan 34
Shenyang 32
Jacksonville 30
Sindelfingen 26
Nanjing 25
New York 24
Verona 22
Falls Church 13
Hebei 12
Helsinki 12
Taiyuan 12
Zhengzhou 12
Tianjin 11
Changsha 10
Nuremberg 10
Perth 10
Redmond 10
Dong Ket 9
Guangzhou 9
Nanchang 9
Redwood City 9
Dallas 8
Santa Clara 8
Seoul 8
Bologna 7
Houston 7
Jakarta 7
Los Angeles 7
Norwalk 7
São Paulo 7
Taizhou 7
Brussels 6
Chengdu 6
Council Bluffs 6
Haikou 6
Kent 6
Ningbo 6
Tokyo 6
Düsseldorf 5
Lomé 5
Milan 5
San Francisco 5
Seattle 5
Bergamo 4
Fairfield 4
London 4
Washington 4
Boardman 3
Canberra 3
Cento 3
Delhi 3
Fremont 3
Fuzhou 3
Goiânia 3
Hangzhou 3
Jiaxing 3
Kochi 3
Kolkata 3
Melbourne 3
Palermo 3
Polska 3
Rio de Janeiro 3
Rome 3
Shanghai 3
Wuhan 3
Baku 2
Belo Horizonte 2
Brasília 2
Brescia 2
Caldiero 2
Cambridge 2
Canoas 2
Chennai 2
Clearwater 2
Duncan 2
Florence 2
Garanhuns 2
Jaú 2
Joinville 2
Juiz de Fora 2
Lanzhou 2
Leawood 2
Mumbai 2
Munich 2
New Haven 2
Newark 2
Nürnberg 2
Osasco 2
Totale 1.796
Salva come PNG Salva come JPEG
Nome #
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 136
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 131
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 129
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 116
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 115
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 97
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 93
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 90
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 90
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 88
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 86
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 84
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 84
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 80
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 76
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 75
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 71
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 70
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 68
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 68
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 65
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 64
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 64
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 62
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 61
Management of Chronic Myeloid Leukemia in Advanced Phase 56
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 56
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 56
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 52
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 49
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 47
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 46
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 44
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 43
Second cancers in MPN: Survival analysis from an international study 36
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 31
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 30
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 28
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 28
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 27
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 26
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 26
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 23
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 13
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 13
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 12
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 12
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 10
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 9
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 6
Totale 2.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.659
article - articoli 10.816
book - libri 0
conference - conferenze 2.843
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.318
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020181 0 0 0 0 0 0 0 0 28 55 60 38
2020/2021241 31 44 11 27 46 28 1 2 3 3 22 23
2021/2022308 31 80 16 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/2025604 46 57 39 187 60 39 83 76 17 0 0 0
Totale 2.942